IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Pitterna, et al.

Serial No.

10/560,390

For

Avermectin B1 Monosaccharide Derivatives

Filed

March 22, 2006

Examiner

Elli Peselev

Group Art Unit

1623

Confirmation No.

2552

3239 Satellite Blvd., Duluth, Georgia 30096-4640 745 Fifth Avenue, New York, New York 10151

Filed via EFS-WEB On March 20, 2009

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The Examiner's attention is respectfully drawn to the documents listed on the accompanying PTO Form 1449.

Pursuant to 37 C.F.R. §1.97, Applicants request the Examiner to consider this Information Disclosure Statement, and to make of record the documents cited on the accompanying PTO form 1449 and that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

The filing of this Information Disclosure Statement is not an admission that the documents identified herein constitutes prior art to the present application.

Pursuant to 37 C.F.R. § 1.97(b)(3), no fees are required as this is being submitted in conjunction with a Request for Continued Examination under 37 C.F.R. § 1.114. While no other fees are believed to be due, the Commissioner is authorized to charge any fees occasion by this paper, or credit any overpayment in fees, to Deposit Account No. 50-0320.

Respectfully submitted,

MERIAL LTD.

FROMMER LAWRENCE & HAUG LLP

By:

Judy Jarecki-Black, Ph.D., J.D.

Reg. No. 44,170

Tel. No. (678) 638-3805

Fax No. (678) 638-3350

Thomas J. Kowalski

Reg. No. 32,147

Deborah L. Lu, Ph.D.

Reg. No. 50,940

Tel. No. (212) 588-0800

Fax No. (212) 588-0500